Home Ingredients SAMe (S-Adenosyl-L-Methionine)
CognitiveLiver HealthDetox & CleanseJoint HealthMood & Mental Health

SAMe (S-Adenosyl-L-Methionine)

Evidence Level
Moderate
4 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP). It plays a critical role in methylation processes, supporting neurotransmitter synthesis, liver detoxification, and joint health. As a dietary supplement, SAMe is used to improve mood, alleviate depression symptoms, support liver function, and reduce osteoarthritis pain. Typical doses range from 400–1600 mg daily, but effects vary, and it may cause side effects like nausea or insomnia. SAMe may interact with antidepressants or other medications. Consult a healthcare provider before use, especially with medical conditions or concurrent medications.

Studied Dose 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach
Active Compound S-Adenosyl-L-Methionine

Benefits

Mood and Depression Support

SAMe may help alleviate symptoms of depression by supporting neurotransmitter production, such as serotonin and dopamine. Studies suggest it can be as effective as some antidepressants for mild-to-moderate depression, with fewer side effects.

Supported by Trial 1, Trial 2

Joint Health and Osteoarthritis

SAMe has anti-inflammatory properties and may stimulate cartilage growth, potentially reducing pain and improving mobility in people with osteoarthritis, particularly in the knees.

Supported by Trial 3, Trial 1

Liver Function

SAMe supports liver health by aiding in detoxification and protecting against liver damage. It may benefit conditions like cholestasis, non-alcoholic fatty liver disease, and hepatitis.

Supported by Trial 3, Trial 4

Cognitive Health

Preliminary research indicates SAMe may support cognitive function and could have a role in managing symptoms of conditions like Alzheimer’s disease, though more studies are needed.

Supported by Trial 2, Trial 3

Fibromyalgia

Some evidence suggests SAMe may reduce pain, fatigue, and stiffness in people with fibromyalgia.

Supported by Trial 3, Trial 1

Methylation Support

SAMe is a key methyl donor in the body, supporting DNA repair, gene expression, and detoxification processes, which are critical for overall health.

Supported by Trial 4, Trial 1

Mechanism of action

1

Methylation Reactions

SAMe is a universal methyl donor, transferring methyl groups to molecules like DNA, proteins, phospholipids, and neurotransmitters. Modifies DNA and histones to control gene activity. Supports production of serotonin, dopamine, and norepinephrine, impacting mood and cognitive function. Methylates phospholipids, maintaining cell membrane integrity. Facilitates the metabolism of toxins and drugs in the liver.

2

Transsulfuration Pathway

SAMe is converted into homocysteine, which enters the transsulfuration pathway to produce glutathione, a potent antioxidant. Enhances detoxification and reduces oxidative stress in conditions like fatty liver disease or hepatitis. Protects cells from oxidative damage.

3

Polyamine Synthesis

SAMe contributes to the synthesis of polyamines. Supports tissue regeneration, including cartilage in osteoarthritis. May aid in maintaining neuronal health.

4

Anti-inflammatory Effects

SAMe reduces pro-inflammatory cytokines (e.g., TNF-α) and increases anti-inflammatory mediators. This contributes to pain relief and improved joint function in osteoarthritis and symptom relief in fibromyalgia.

5

Neurotransmitter Modulation

By supporting methylation, SAMe enhances the synthesis and metabolism of neurotransmitters, which may explain its antidepressant effects and potential benefits in cognitive disorders.

Clinical trials

1
SAMe as SSRI Augmentation for Depression — Clinical Trial

Randomized, double-blind, placebo-controlled trial (NCT00093847) evaluating SAMe as adjunct to serotonin reuptake inhibitors in depressed patients. (Am J Psychiatry)

Depressed adults on SSRIs.

SAMe augmentation modestly improved response and remission rates vs placebo when added to SSRIs. Note: depression management primarily uses SSRIs/SNRIs/atypical antidepressants + CBT/psychotherapy. SAMe is a reasonable adjunctive option for partial responders.

2
SAMe Monotherapy for MDD — Phase II Clinical Trial

Phase II trial (NCT01912196) of SAMe monotherapy (800-1,600 mg/day) vs placebo in 60 patients with MDD.

60 MDD patients.

SAMe modestly reduced depression scores vs placebo as monotherapy. Effect sizes modest. Note: small Phase II — not large definitive trial. SAMe vs SSRI head-to-head trials have shown comparable efficacy in some studies but with substantially higher cost.

3
SAMe vs Celecoxib for Knee OA — Clinical Trial

Clinical trial (NCT00133341) of SAMe (1,200 mg/day) vs celecoxib (200 mg/day) vs placebo in 120 patients with knee OA. (BMC Musculoskelet Disord — earlier; or related)

120 knee OA patients.

SAMe and celecoxib produced comparable pain and function improvements vs placebo. Slower onset for SAMe (1 month vs days for celecoxib). Note: NSAID alternatives clinically valuable; SAMe lacks GI/cardiovascular toxicity of NSAIDs.

4
SAMe for Depression in Parkinson's Disease — Open-Label Pilot

Pilot, open-label study (NCT00070941) of SAMe (800-2,400 mg/day) in 21 patients with Parkinson's disease and depression.

21 PD + depression patients.

Modest improvements in depression scores. Critical caveat: open-label (no placebo, not blinded) — inflated effect estimate. Pilot only. Note: PD-related depression is challenging; SSRIs first-line; consider drug-drug interactions in PD pharmacotherapy.

Side effects and drug interactions

Common Potential side effects

Gastrointestinal: Nausea, diarrhea, upset stomach, bloating, or mild abdominal pain are frequently reported, especially at higher doses.
Nervous System: Headache, dizziness, or mild insomnia may occur, particularly if taken later in the day due to its potential to increase energy or alertness.
Psychiatric: Anxiety, restlessness, or irritability can occur, especially in sensitive individuals or at high doses.

Important Drug interactions

Antidepressants (MAOIs, SSRIs, SNRIs, tricyclics) — serious serotonin syndrome risk; never combine with MAOIs; use extreme caution with SSRIs
Levodopa — SAMe may reduce levodopa efficacy in Parkinson's disease; avoid concurrent use
Warfarin — SAMe may enhance anticoagulant effects; monitor INR closely

Featured in these supplement guides

Joint Pain→

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Explore Other Ingredients

Antioxidant
Dandelion Root
Dandelion root is a traditional herb used to support liver and digestive health and as a g…
Antioxidant
Alpha Lipoic Acid
Alpha-lipoic acid (ALA) is a versatile antioxidant made naturally in the body that is unus…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…

Frequently asked questions about SAMe (S-Adenosyl-L-Methionine)

What is SAMe used for?

SAMe (S-adenosyl-L-methionine) is a compound the body makes from methionine, used for mood support (depression), joint comfort (osteoarthritis), and liver health. It is involved in many methylation reactions throughout the body.

Does SAMe help with mood and joints?

SAMe has notable research for supporting mood (comparable to some antidepressants in studies) and for easing osteoarthritis joint discomfort, making it one of the better-evidenced supplements for these uses. Give it a few weeks.

How much SAMe should I take?

Mood studies use about 400 to 1,600 mg per day, and joint studies similar; it is taken on an empty stomach, and enteric-coated forms are preferred for stability. Start low and follow product labeling.

Is SAMe safe?

It is generally well tolerated; it can cause nausea or, in susceptible people, anxiety or (rarely) mania. It should not be combined with antidepressants or other serotonergic drugs without medical guidance, and those with bipolar disorder should avoid it. Check with your doctor.

What is SAMe?

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP). It plays a critical role in methylation processes, supporting neurotransmitter synthesis, liver detoxification, and joint health.

What is the recommended dosage of SAMe?

The clinically studied dose is 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach Always follow the product label and check with a healthcare provider for personal advice.

Is SAMe safe, and does it have side effects?

For most healthy adults, SAMe is well tolerated at studied doses. Reported effects can include: Gastrointestinal: Nausea, diarrhea, upset stomach, bloating, or mild abdominal pain are frequently reported, especially at higher doses. Nervous System: Headache, dizziness, or mild insomnia may occur, particularly if taken later in the day due to its potential to increase energy… It may also interact with some medications. SAMe is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does SAMe interact with any medications?

Possible interactions include: Antidepressants (MAOIs, SSRIs, SNRIs, tricyclics) — serious serotonin syndrome risk; never combine with MAOIs; use extreme caution with SSRIs Levodopa — SAMe may reduce levodopa efficacy in Parkinson's disease; avoid concurrent use If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for SAMe?

NutraSmarts rates the evidence for SAMe as Moderate (3 out of 5). It is backed by 4 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Limveeraprajak N, Nakhawatchana S, Visukamol A, et al. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2024;132:110985..PubMedUsed to support: Systematic review/meta-analysis supporting SAMe for depression.